Regeneron Pharmaceuticals Inc (REGN)

Quick ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash	US$ in thousands	2,730,000	2,152,300	1,937,200	3,916,300	3,105,900	3,491,300	3,395,100	3,345,700	2,885,600	3,432,400	2,072,200	1,437,900	2,193,700	1,573,000	1,992,200	2,208,200	1,617,800	1,384,800	1,045,500	1,708,500
Short-term investments	US$ in thousands	8,114,800	7,761,300	6,990,500	5,043,400	4,636,400	3,530,400	4,171,300	3,704,900	2,809,100	2,355,200	1,838,600	2,065,900	1,393,300	1,452,900	1,152,000	1,795,200	1,596,500	1,493,100	1,624,200	1,523,900
Receivables	US$ in thousands	5,667,300	5,584,500	5,121,300	5,118,600	5,328,700	5,548,300	5,161,400	4,839,000	6,036,500	5,452,000	6,998,600	4,173,000	3,111,500	3,553,300	2,380,200	2,531,400	2,360,600	2,373,100	2,172,200	2,016,000
Total current liabilities	US$ in thousands	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200	2,096,600	1,765,400	1,713,100	1,511,400
Quick ratio		4.82	4.31	4.53	4.54	4.16	4.37	4.20	3.95	2.98	3.03	2.92	2.39	2.48	2.81	1.49	3.18	2.66	2.97	2.83	3.47

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,730,000K + $8,114,800K + $5,667,300K) ÷ $3,423,400K
= 4.82

The quick ratio of Regeneron Pharmaceuticals, Inc. has been consistently high over the past eight quarters, ranging from 4.09 to 4.94. This indicates that the company has a strong ability to meet its short-term obligations using its most liquid assets. A quick ratio above 1 typically suggests that the company is capable of covering its current liabilities with its quick assets, such as cash, marketable securities, and accounts receivable, which are readily convertible into cash.

The upward trend in the quick ratio from Q1 2022 to Q4 2023 indicates an improvement in Regeneron's liquidity position. This trend suggests that the company has been effective in managing its short-term assets and liabilities, maintaining a healthy financial position.

Overall, the consistently high quick ratio of Regeneron Pharmaceuticals, Inc. reflects a robust liquidity position, which can contribute to the company's ability to fund its operations, invest in growth opportunities, and weather potential financial challenges.